

Hamamatsu Photonics expands intended use of NanoZoomer[®] MD Series in Europe to include cytology

Expanded intended use helps pathology laboratories unify histology and cytology digitization

News provided by:
Hamamatsu Photonics Europe
April 28, 2026

Share this article:



Hamamatsu Photonics is pleased to announce an expansion of the intended use of the NanoZoomer MD series in Europe to include cytology slide digitization. The expanded clinical application scope supports laboratories seeking greater consistency, efficiency, and diagnostic confidence in cellular image evaluation.



NanoZoomer MD series. Systems are required to operate with a cart in actual conditions. Photo: ©Hamamatsu Photonics

Enhanced digital capabilities for cytology

The expanded intended use is supported by findings from the recently published study *Validation of Digital Cytology for Primary Diagnosis Across a Range of Specimen Types*, conducted by researchers at University College London and University College London Hospitals NHS Foundation Trust and published in *Cytopathology* ^[1]. With the expanded intended use, the

NanoZoomer MD series in Europe can now be used to acquire digital images from a broad range of cytology preparations, including:

- Conventional Pap smears
- Liquid-based cytology samples
- Non-gynecological preparations
- Fine-needle aspirates (FNAs)

Cytology evaluation depends on fine detail recognition, nuclear features, and subtle chromatic differences. The NanoZoomer MD series in Europe supports these needs through:

- High-resolution optical capture for accurate visualization
- Consistent color reproduction to support reproducible assessments
- Automated focus and scanning stability

The result is a reliable digital environment that supports pathologists in delivering high-quality clinical evaluations.

Enabling laboratories in their digital transformation

By incorporating cytology into its intended use, the NanoZoomer MD series in Europe gives pathology institutions the ability to:

- Consolidate histology and cytology on a single digital platform
- Accelerate case review and remote collaboration
- Support long-term digital archiving strategies

Commitment to pathology excellence

This expansion reflects Hamamatsu's ongoing commitment to enabling fully digital workflows across the spectrum of pathology, including both histology and cytology, and aligns with increasing clinical demand for high-quality digital images for routine review, consultation, and archiving.



"We are proud to broaden the intended use of the NanoZoomer MD Series," said Martin Kristensson, Strategic Marketing Manager at Hamamatsu Photonics Europe. *"Cytology has been a key request from our clinical partners, and this expansion reinforces Hamamatsu's long-standing commitment to providing high precision, clinically validated imaging solutions that meet the evolving needs of modern pathology."*

References

[1] T. Mistry, H. Hunter, D. Oukrif, S. Pomplun, R. Patel, M. Rodriguez-Justo, and A. P. Levine, "Validation of digital cytology for primary diagnosis across a range of specimen types," *Cytopathology*, Mar. 10, 2026. [Online]. Available: [doi:10.1111/cyt.70063](https://doi.org/10.1111/cyt.70063).